Hypoxen 250 mg 30 capsules
Plaquenil 200 mg 60 tablets
Sialis 5 mg 14 tablets
Tamiflu 75 mg 10 capsules
Cerebrolysin 5 ml 5 vials
Ovestin 2 mg 30 tablets
Ovestin Vaginal cream 15g
Macmiror 200 mg 20 tablets
Ventolin nebula 20 ampoules
Avodart 0,5 mg 90 capsules
- Antibacterial medication
- Antifungal medication
- Antiviral Medication
- Cardiovascular medication
- different medication
- Hormonal medication
- Immunosuppressants and immunomodulating medications
- Nervous system
- Pain relievers and anti-inflammatory
- Respiratory system
- Treatment of diseases of the liver and gastrointestinal tract
- Treatment of sensory organs, eyesight and hearing
- Urogenital system
Piracetam 800 mg 30 tablets
De-Nol 120mg 112 tablets
De-Nol 120mg 56 tablets
De-Nol 120mg 32 tablets
finasteride 5mg 30 tablets
Itrazole 100 mg 42 capsules
furasol 15 sachets of 100 mg
Triacort OINTMENT 0.1% 10G
Urseptia 200 mg 20 capsules
Minolexin 50 mg 20 capsules
Immard 200 mg 30 tablets
Adenuric 120 mg 28 tablets
Champix 1 mg 112 tablets
Ingavirin 90 mg 10 capsues
Donormil 30 tablets
Vestibo 24 mg 30 tablets
betaserc 8 mg 30 tablets
Ceraxon 500 mg/4 ml 5 vials
tagista 16 mg 30 tablets
Ceraxon 1000 mg/4 ml 5 vials
Semax nasal drops 0.1% 3 ml
Memantine 10 mg 30 tablets
Axamon 20 mg 50 tablets
Deprim 30 tablets
Fezam 60 Capsules
Persen 60 tablets
Vasobral 30 tablets
Melaxen 3 mg 12 tablets
Baclosan 25 mg 50 tablets
Cogitum 10 ml 30 vials
Persen 20 tablets
Zonegran 25 mg 14 tablets
Betahistine 24 mg 60 tablets
Cerebrolysin 2 ml 10 vials
Vinpocetine 5 mg 50 tablets
Atorvastatin 20 mg 30 tablets
Manufacturer: various options
Country of origin: Russia
General description: lipid-lowering drugs
Pharmacological action
A hypolipidemic agent from the group of statins. By the principle of competitive antagonism, the statin molecule binds to that part of the coenzyme A receptor where the HMG-CoA reductase is attached. Another part of the statin molecule inhibits the conversion of hydroxymethylglutarate to mevalonate, an intermediate in the synthesis of the cholesterol molecule. Inhibition of the activity of HMG-CoA reductase results in a series of consecutive reactions that result in a decrease in intracellular cholesterol and a compensatory increase in LDL receptor activity and, accordingly, acceleration of LDL cholesterol catabolism (Xc).
The hypolipidemic effect of statins is associated with a decrease in the level of total cholesterol due to Xc-LDL. The decrease in LDL is dose-dependent and has a non-linear, but an exponential nature. The inhibitory effect of atorvastatin on HMG-CoA reductase is approximately 70% determined by the activity of its circulating metabolites.
Statins do not affect the activity of lipoprotein and hepatic lipases, they do not have a significant effect on the synthesis and catabolism of free fatty acids, so their effect on the level of TG is secondary and mediated through their main effects on lowering the level of LDL-C. The moderate decrease in TG levels in statin therapy appears to be due to the expression of the receptor (apo E) receptors on the surface of hepatocytes participating in the catabolism of the disease, which includes approximately 30% TG. Compared to other statins (with the exception of rosuvastatin), atorvastatin causes a more pronounced decrease in TG levels.
In addition to lipid-lowering effects, statins have a positive effect on endothelial dysfunction (preclinical signs of early atherosclerosis), on the vascular wall, atheroma state, improve the rheological properties of blood, and possess antioxidant, antiproliferative properties.
Atorvastatin reduces cholesterol in patients with homozygous familial hypercholesterolemia, which usually does not respond to lipid-lowering therapy.
Indications
Primary hypercholesterolemia (heterozygous familial and non-family hypercholesterolemia (type IIa according to Fredrickson classification), combined (mixed) hyperlipidemia (types IIa and IIb according to Fredrickson classification), disbetalipoproteinemia (type III according to Fredrickson classification) (as a supplement to the diet), family endogenous hypertriglyceridemia (type IV according to Fredrickson classification), resistant to diet, homozygous familial hypercholesterolemia with insufficient effectiveness of diet therapy and other non-pharmacological methods of lech
Primary prophylaxis of cardiovascular complications in patients without clinical signs of IHD, but having several risk factors for its development - age over 55, nicotine dependence, arterial hypertension, diabetes mellitus, low concentrations of HDL-C in the blood plasma, genetic predisposition, h. against the background of dyslipidemia.
Secondary prophylaxis of cardiovascular complications in patients with ischemic heart disease in order to reduce the total death rate, myocardial infarction, stroke, re-hospitalization for angina pectoris and the need for revascularization.


.